GSK (NYSE:GSK) & CorMedix (NASDAQ:CRMD) Critical Survey

CorMedix (NASDAQ:CRMD) and GSK (NYSE:GSK) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, earnings, dividends and risk.

Profitability

This table compares CorMedix and GSK’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CorMedix	40.49%	40.52%	20.61%
GSK	14.56%	43.23%	11.60%

Analyst Recommendations

This is a summary of current ratings and price targets for CorMedix and GSK, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CorMedix	0	2	7	0	2.78
GSK	2	7	1	1	2.09

CorMedix currently has a consensus price target of $15.00, indicating a potential upside of 106.04%. GSK has a consensus price target of $56.50, indicating a potential upside of 20.20%. Given CorMedix’s stronger consensus rating and higher probable upside, research analysts plainly believe CorMedix is more favorable than GSK.

Earnings & Valuation

This table compares CorMedix and GSK”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CorMedix	$311.71 million	1.82	$163.05 million	$2.14	3.40
GSK	$43.07 billion	2.21	$7.54 billion	$3.20	14.69

GSK has higher revenue and earnings than CorMedix. CorMedix is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

34.2% of CorMedix shares are owned by institutional investors. Comparatively, 15.7% of GSK shares are owned by institutional investors. 3.5% of CorMedix shares are owned by company insiders. Comparatively, 10.0% of GSK shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Risk and Volatility

CorMedix has a beta of 1.4, meaning that its stock price is 40% more volatile than the S&P 500. Comparatively, GSK has a beta of 0.33, meaning that its stock price is 67% less volatile than the S&P 500.

Summary

GSK beats CorMedix on 8 of the 15 factors compared between the two stocks.

About CorMedix

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.